MET and hepatocellular carcinoma: Additionally, metformin has been found to reduce phospho-ERK and Cyclin D1 and c-Myc expression in AKT/c-Met mice and hindered the malignant transformation of hepatocytes in an AKT/c-Met-activated HCC mouse model (Zhang et al., 2019).